🇺🇸 FDA
Patent

US 8039623

Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

granted A61KA61K38/08A61P

Quick answer

US patent 8039623 (Inhibitors of serine proteases, particularly HCV NS3-NS4A protease) held by Vertex Pharmaceuticals Incorporated expires Mon Oct 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Oct 18 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K38/08, A61P, A61P1/16, A61P31/12